HR6626-119

In Committee

PFAS Accountability Act of 2025

119th Congress Introduced Dec 11, 2025

Summary

What This Bill Does

The PFAS Accountability Act amends the Toxic Substances Control Act to create a federal legal claim for people significantly exposed to perfluoroalkyl or polyfluoroalkyl substances. Individuals, including class representatives, may sue in federal district court for legal and equitable relief against parties that manufactured PFAS or used PFAS in manufacturing processes tied to the exposure. The bill treats significant PFAS exposure as an injury in law and equity, authorizes medical monitoring, allows courts to shift testing and monitoring costs to responsible parties, and is designed to encourage PFAS safety research by making irresponsible manufacturing more legally costly. It preserves state-law claims and remedies rather than preempting them.

Who Benefits and How

Individuals significantly exposed to PFAS benefit because they can bring a federal claim before disease is fully manifest and seek medical monitoring. Communities near PFAS contamination sites benefit from cost shifting that can move testing expenses from exposed residents to responsible manufacturers. Public-health researchers and clinicians benefit from incentives for PFAS safety research and monitoring data. Plaintiffs attorneys benefit from a clearer federal cause of action and class-action pathway.

Who Bears the Burden and How

PFAS manufacturers and companies that used PFAS in manufacturing face litigation exposure, medical-monitoring costs, testing obligations, and potential equitable relief. Federal courts must manage new PFAS cases and class claims under TSCA. Defendants may need to preserve manufacturing records, exposure evidence, and safety research. Insurers and corporate compliance teams may face higher liability-management costs. Federal taxpayers bear court-system workload if PFAS filings increase.

Key Provisions

  • Creates a federal TSCA cause of action for individuals significantly exposed to PFAS.
  • Authorizes individual or class claims in federal district court for legal and equitable relief.
  • Requires responsible PFAS manufacturers and industrial PFAS users to face medical-monitoring and testing-cost exposure.
  • Provides significant PFAS exposure treatment as an injury at law and equity for monitoring claims.
  • Protects state-law claims and remedies alongside the new federal cause of action.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

Creates a Toxic Substances Control Act federal cause of action for individuals significantly exposed to PFAS, authorizes medical monitoring and other equitable relief, shifts testing and monitoring costs to responsible PFAS manufacturers or users, and preserves state-law remedies.

Key Policy Areas

PFAS, Environmental Health, Civil Litigation, Chemical Manufacturing

Primary Purpose

Creates a Toxic Substances Control Act federal cause of action for individuals significantly exposed to PFAS, authorizes medical monitoring and other equitable relief, shifts testing and monitoring costs to responsible PFAS manufacturers or users, and preserves state-law remedies.

Policy Domains

PFAS Environmental Health Civil Litigation Chemical Manufacturing

Substantive provisions

Identified Gains
  • Individuals significantly exposed to PFAS
  • Contaminated communities
  • Public-health researchers
  • Clinicians
  • Plaintiffs attorneys
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
Clinicians: , ,
Plaintiffs attorneys: , ,
Contaminated communities: , ,
Public-health researchers: , ,
Individuals significantly exposed to PFAS: , ,
Identified Costs
  • PFAS manufacturers
  • Industrial PFAS users
  • Federal courts
  • Corporate compliance teams
  • Insurers
  • Federal taxpayers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
Insurers: , ,
Federal courts: , ,
Federal taxpayers: , ,
PFAS manufacturers: , ,
Industrial PFAS users: , ,
Corporate compliance teams: , ,

Legislative Progress

In Committee
Introduced Committee Passed
Dec 11, 2025

Ms. Dean of Pennsylvania (for herself, Mrs. Dingell, Mr. Nadler, …

Dec 11, 2025

Referred to the Committee on Energy and Commerce, and in …

Dec 11, 2025

Introduced in House

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Manufacturing
3 mentions across 2 clauses
-3 negative

Industrial PFAS users, PFAS manufacturers, PFAS manufacturers and other defendants subject to new Federal PFAS exposure suits and monitoring liability

General Public
2 mentions across 2 clauses
+2 positive

Individuals significantly exposed to PFAS, Individuals significantly exposed to PFAS who may sue and seek medical monitoring

Government
1 mention across 1 clause
-1 negative

Federal courts

Professional Services
1 mention across 1 clause
+1 positive

Plaintiffs attorneys

3/5
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
PFAS Environmental Health Civil Litigation Chemical Manufacturing
Actor Mappings
"PFAS"
→ Perfluoroalkyl and polyfluoroalkyl substances
"TSCA"
→ Toxic Substances Control Act

Key Definitions

Terms defined in this bill

2 terms
"" §PFAS

"" §medical monitoring

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology